Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Amplification of the mutation-carrying BRCA2 allele promotes RAD51 loading and PARP inhibitor resistance in the absence of reversion mutations.

Park PH, Yamamoto TM, Li H, Alcivar AL, Xia B, Wang Y, Bernhardy AJ, Turner KM, Kossenkov AV, Watson ZL, Behbakht K, Casadei S, Swisher EM, Mischel PS, Johnson N, Bitler BG.

Mol Cancer Ther. 2019 Oct 1. pii: molcanther.0256.2019. doi: 10.1158/1535-7163.MCT-17-0256. [Epub ahead of print]

PMID:
31575654
2.

Multi-Omic Approaches Identify Metabolic and Autophagy Regulators Important in Ovarian Cancer Dissemination.

Wheeler LJ, Watson ZL, Qamar L, Yamamoto TM, Sawyer BT, Sullivan KD, Khanal S, Joshi M, Ferchaud-Roucher V, Smith H, Vanderlinden LA, Brubaker SW, Caino CM, Kim H, Espinosa JM, Richer JK, Bitler BG.

iScience. 2019 Sep 27;19:474-491. doi: 10.1016/j.isci.2019.07.049. Epub 2019 Aug 6.

3.

Adiponectin receptor agonist AdipoRon induces apoptotic cell death and suppresses proliferation in human ovarian cancer cells.

Ramzan AA, Bitler BG, Hicks D, Barner K, Qamar L, Behbakht K, Powell T, Jansson T, Wilson H.

Mol Cell Biochem. 2019 Nov;461(1-2):37-46. doi: 10.1007/s11010-019-03586-9. Epub 2019 Jul 10.

PMID:
31292831
4.

Activation of Wnt signaling promotes olaparib resistant ovarian cancer.

Yamamoto TM, McMellen A, Watson ZL, Aguilera J, Ferguson R, Nurmemmedov E, Thakar T, Moldovan GL, Kim H, Cittelly DM, Joglar AM, Brennecke EP, Wilson H, Behbakht K, Sikora MJ, Bitler BG.

Mol Carcinog. 2019 Oct;58(10):1770-1782. doi: 10.1002/mc.23064. Epub 2019 Jun 10.

PMID:
31219654
5.

Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer.

Dahl ES, Buj R, Leon KE, Newell JM, Imamura Y, Bitler BG, Snyder NW, Aird KM.

Mol Cancer Res. 2019 Aug;17(8):1710-1720. doi: 10.1158/1541-7786.MCR-18-1233. Epub 2019 May 20.

PMID:
31110157
6.

Ovarian Tumor Cell Expression of Claudin-4 Reduces Apoptotic Response to Paclitaxel.

Breed C, Hicks DA, Webb PG, Galimanis CE, Bitler BG, Behbakht K, Baumgartner HK.

Mol Cancer Res. 2019 Mar;17(3):741-750. doi: 10.1158/1541-7786.MCR-18-0451. Epub 2019 Jan 3.

PMID:
30606772
7.

Type I Protein Arginine Methyltransferases Overexpression Promotes Transformation and Potentiates Her2/Neu-Driven Tumorigenesis.

Watson ZL, Bitler BG.

Cancer Res. 2019 Jan 1;79(1):3-4. doi: 10.1158/0008-5472.CAN-18-3552.

PMID:
30602621
8.

Epigenetic inhibitors for the precision treatment of ARID1A-mutant ovarian cancers: what are the next steps?

Fukumoto T, Zhang R, Bitler BG.

Expert Rev Precis Med Drug Dev. 2018;3(4):233-236. doi: 10.1080/23808993.2018.1503050. Epub 2018 Jul 25. No abstract available.

9.

CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer.

Wheeler LJ, Watson ZL, Qamar L, Yamamoto TM, Post MD, Berning AA, Spillman MA, Behbakht K, Bitler BG.

Oncogenesis. 2018 Nov 26;7(11):92. doi: 10.1038/s41389-018-0103-1.

10.

SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.

Wu S, Fatkhutdinov N, Fukumoto T, Bitler BG, Park PH, Kossenkov AV, Trizzino M, Tang HY, Zhang L, Gardini A, Speicher DW, Zhang R.

Nat Commun. 2018 Oct 8;9(1):4116. doi: 10.1038/s41467-018-06656-6.

11.

The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing.

Gordon MA, Babbs B, Cochrane DR, Bitler BG, Richer JK.

Mol Carcinog. 2019 Feb;58(2):196-205. doi: 10.1002/mc.22919. Epub 2018 Oct 28.

PMID:
30294913
12.

CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer.

Singha B, Harper SL, Goldman AR, Bitler BG, Aird KM, Borowsky ME, Cadungog MG, Liu Q, Zhang R, Jean S, Drapkin R, Speicher DW.

Sci Rep. 2018 Oct 3;8(1):14725. doi: 10.1038/s41598-018-32885-2.

13.

Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.

Fukumoto T, Park PH, Wu S, Fatkhutdinov N, Karakashev S, Nacarelli T, Kossenkov AV, Speicher DW, Jean S, Zhang L, Wang TL, Shih IM, Conejo-Garcia JR, Bitler BG, Zhang R.

Cell Rep. 2018 Mar 27;22(13):3393-3400. doi: 10.1016/j.celrep.2018.03.019.

14.

CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity.

Karakashev S, Zhu H, Wu S, Yokoyama Y, Bitler BG, Park PH, Lee JH, Kossenkov AV, Gaonkar KS, Yan H, Drapkin R, Conejo-Garcia JR, Speicher DW, Ordog T, Zhang R.

Nat Commun. 2018 Feb 12;9(1):631. doi: 10.1038/s41467-018-03031-3.

15.

BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.

Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N, Kossenkov AV, Wilson AJ, Simpkins F, Speicher D, Khabele D, Bitler BG, Zhang R.

Cell Rep. 2017 Dec 19;21(12):3398-3405. doi: 10.1016/j.celrep.2017.11.095.

16.

PARP inhibitors: Clinical utility and possibilities of overcoming resistance.

Bitler BG, Watson ZL, Wheeler LJ, Behbakht K.

Gynecol Oncol. 2017 Dec;147(3):695-704. doi: 10.1016/j.ygyno.2017.10.003. Epub 2017 Oct 14. Review.

17.

ARID1A-mutated ovarian cancers depend on HDAC6 activity.

Bitler BG, Wu S, Park PH, Hai Y, Aird KM, Wang Y, Zhai Y, Kossenkov AV, Vara-Ailor A, Rauscher FJ III, Zou W, Speicher DW, Huntsman DG, Conejo-Garcia JR, Cho KR, Christianson DW, Zhang R.

Nat Cell Biol. 2017 Aug;19(8):962-973. doi: 10.1038/ncb3582. Epub 2017 Jul 24.

18.

Developmental Expression of Claudins in the Mammary Gland.

Baumgartner HK, Rudolph MC, Ramanathan P, Burns V, Webb P, Bitler BG, Stein T, Kobayashi K, Neville MC.

J Mammary Gland Biol Neoplasia. 2017 Jun;22(2):141-157. doi: 10.1007/s10911-017-9379-6. Epub 2017 Apr 28.

19.

BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer.

Yokoyama Y, Zhu H, Lee JH, Kossenkov AV, Wu SY, Wickramasinghe JM, Yin X, Palozola KC, Gardini A, Showe LC, Zaret KS, Liu Q, Speicher D, Conejo-Garcia JR, Bradner JE, Zhang Z, Sood AK, Ordog T, Bitler BG, Zhang R.

Cancer Res. 2016 Nov 1;76(21):6320-6330.

20.

The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.

Goldman AR, Bitler BG, Schug Z, Conejo-Garcia JR, Zhang R, Speicher DW.

Mol Cell Proteomics. 2016 Nov;15(11):3348-3360. Epub 2016 Sep 21.

21.

HMGB2 orchestrates the chromatin landscape of senescence-associated secretory phenotype gene loci.

Aird KM, Iwasaki O, Kossenkov AV, Tanizawa H, Fatkhutdinov N, Bitler BG, Le L, Alicea G, Yang TL, Johnson FB, Noma KI, Zhang R.

J Cell Biol. 2016 Nov 7;215(3):325-334. Epub 2016 Oct 31.

22.

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG, Allegrezza MJ, Yokoyama Y, Kossenkov AV, Bradner JE, Conejo-Garcia JR, Zhang R.

Cell Rep. 2016 Sep 13;16(11):2829-2837. doi: 10.1016/j.celrep.2016.08.032.

23.

Arid1a controls tissue regeneration.

Wu S, Zhang R, Bitler BG.

Stem Cell Investig. 2016 Aug 9;3:35. doi: 10.21037/sci.2016.07.07. eCollection 2016. No abstract available.

24.

Epigenetic synthetic lethality in ovarian clear cell carcinoma: EZH2 and ARID1A mutations.

Bitler BG, Aird KM, Zhang R.

Mol Cell Oncol. 2015 Apr 14;3(1):e1032476. doi: 10.1080/23723556.2015.1032476. eCollection 2016 Jan.

25.

SPOP E3 Ubiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase.

Zhu H, Ren S, Bitler BG, Aird KM, Tu Z, Skordalakes E, Zhu Y, Yan J, Sun Y, Zhang R.

Cell Rep. 2015 Nov 10;13(6):1183-1193. doi: 10.1016/j.celrep.2015.09.083. Epub 2015 Oct 29.

26.

Potential therapeutic targets in ARID1A-mutated cancers.

Bitler BG, Fatkhutdinov N, Zhang R.

Expert Opin Ther Targets. 2015;19(11):1419-22. doi: 10.1517/14728222.2015.1062879. Epub 2015 Jun 30. Review.

27.

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.

Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV, Schultz DC, Liu Q, Shih IeM, Conejo-Garcia JR, Speicher DW, Zhang R.

Nat Med. 2015 Mar;21(3):231-8. doi: 10.1038/nm.3799. Epub 2015 Feb 16.

28.

A high-content screening assay for small-molecule modulators of oncogene-induced senescence.

Bitler BG, Fink LS, Wei Z, Peterson JR, Zhang R.

J Biomol Screen. 2013 Oct;18(9):1054-61. doi: 10.1177/1087057113491827. Epub 2013 Jun 3.

29.

Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence.

Aird KM, Zhang G, Li H, Tu Z, Bitler BG, Garipov A, Wu H, Wei Z, Wagner SN, Herlyn M, Zhang R.

Cell Rep. 2013 Apr 25;3(4):1252-65. doi: 10.1016/j.celrep.2013.03.004. Epub 2013 Apr 4.

30.

NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells.

Garipov A, Li H, Bitler BG, Thapa RJ, Balachandran S, Zhang R.

Mol Cancer Res. 2013 Apr;11(4):360-9. doi: 10.1158/1541-7786.MCR-12-0661. Epub 2013 Jan 29.

31.

MUC1 drives c-Met-dependent migration and scattering.

Horm TM, Bitler BG, Broka DM, Louderbough JM, Schroeder JA.

Mol Cancer Res. 2012 Dec;10(12):1544-54. doi: 10.1158/1541-7786.MCR-12-0296. Epub 2012 Nov 27.

32.

ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches.

Li H, Bitler BG, Vathipadiekal V, Maradeo ME, Slifker M, Creasy CL, Tummino PJ, Cairns P, Birrer MJ, Zhang R.

Cancer Prev Res (Phila). 2012 Mar;5(3):484-91. doi: 10.1158/1940-6207.CAPR-11-0414. Epub 2011 Dec 5.

33.

Oncogenic RAS regulates BRIP1 expression to induce dissociation of BRCA1 from chromatin, inhibit DNA repair, and promote senescence.

Tu Z, Aird KM, Bitler BG, Nicodemus JP, Beeharry N, Xia B, Yen TJ, Zhang R.

Dev Cell. 2011 Dec 13;21(6):1077-91. doi: 10.1016/j.devcel.2011.10.010. Epub 2011 Dec 1.

34.

Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence.

Bitler BG, Nicodemus JP, Li H, Cai Q, Wu H, Hua X, Li T, Birrer MJ, Godwin AK, Cairns P, Zhang R.

Cancer Res. 2011 Oct 1;71(19):6184-94. doi: 10.1158/0008-5472.CAN-11-1341. Epub 2011 Aug 4.

35.

Derlin-dependent retrograde transport from endosomes to the Golgi apparatus.

Dang H, Klokk TI, Schaheen B, McLaughlin BM, Thomas AJ, Durns TA, Bitler BG, Sandvig K, Fares H.

Traffic. 2011 Oct;12(10):1417-31. doi: 10.1111/j.1600-0854.2011.01243.x. Epub 2011 Jul 27.

36.

MUC1 regulates nuclear localization and function of the epidermal growth factor receptor.

Bitler BG, Goverdhan A, Schroeder JA.

J Cell Sci. 2010 May 15;123(Pt 10):1716-23. doi: 10.1242/jcs.062661. Epub 2010 Apr 20.

37.

Anti-cancer therapies that utilize cell penetrating peptides.

Bitler BG, Schroeder JA.

Recent Pat Anticancer Drug Discov. 2010 Jun;5(2):99-108. Review.

PMID:
19961434
38.

Genetic diversification and demographic history of the cactophilic pseudoscorpion Dinocheirus arizonensis from the Sonoran Desert.

Pfeiler E, Bitler BG, Castrezana S, Matzkin LM, Markow TA.

Mol Phylogenet Evol. 2009 Jul;52(1):133-41. doi: 10.1016/j.ympev.2008.12.020. Epub 2008 Dec 31.

39.

Intracellular MUC1 peptides inhibit cancer progression.

Bitler BG, Menzl I, Huerta CL, Sands B, Knowlton W, Chang A, Schroeder JA.

Clin Cancer Res. 2009 Jan 1;15(1):100-9. doi: 10.1158/1078-0432.CCR-08-1745.

40.

Transforming growth factor alpha dependent cancer progression is modulated by Muc1.

Pochampalli MR, Bitler BG, Schroeder JA.

Cancer Res. 2007 Jul 15;67(14):6591-8.

41.

Functional genomics of cactus host shifts in Drosophila mojavensis.

Matzkin LM, Watts TD, Bitler BG, Machado CA, Markow TA.

Mol Ecol. 2006 Dec;15(14):4635-43.

PMID:
17107489

Supplemental Content

Loading ...
Support Center